Nanomedicine Breakthrough Redefines Oncology Drug Delivery

This report focuses on a major shift in the oncology market toward advanced drug delivery systems, specifically nanomedicine. It highlights how poor bioavailability limits the effectiveness of traditional cancer drugs and presents Oncotelic Therapeutics Inc.’s Deciparticle platform as a solution designed to significantly increase drug absorption and reduce toxicity. The article details the platform’s versatility, its clinical momentum with the advancement of Sapu-003 (Deciparticle Everolimus) into human trials, and the projection that the nanomedicine market will surpass $500 billion by 2032, driven by delivery innovation. Continue reading